Perseus Proteomics, Inc. (JP:4882) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Perseus Proteomics, Inc. has announced promising results from the phase I clinical trial of its novel antibody PPMX-T003, targeting polycythemia vera, presented at the ASH Annual Meeting. The trial demonstrated safety and potential efficacy, as participants experienced a 12-week period without phlebotomy and no serious side effects. This development marks a significant step forward for the company’s innovative antibody therapies.
For further insights into JP:4882 stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Shareholder Alert for Celsius Holdings, Inc. (NASDAQ:CELH)
- ‘Don’t Chase the Rally,’ Says Investor About Archer Aviation Stock
- ‘Robotaxi Is No Game-Changer,’ Says Analyst About Tesla Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
